| Popis: |
The use of CSII is progressively growing throughout the world, however a number of factors interfere with its diffusion and produce wide disparity between different countries. In USA around 20–25% of the population of Type 1 diabetics is treated with CSII, while in Europe the application ranges from nearly 0% in countries like UK and Denmark and 10% in Sweden, the Netherlands and Germany. The reasons for such differences are mostly economic and are likely to be even more accentuated in the next future due to the expected introduction in the market of more sophisticated and expensive instruments. A strong educational action seems to be necessary in order to convince the relevant payers to reimburse CSII as it has already proven its efficacy and effectiveness in improving the metabolic control and the quality of life of a well defined fraction of people with Type 1 diabetes. |
Full Text from ScienceDirect